Imiquimod-d<sub>9</sub>

Imiquimod-d9

CAT N°: 26424
Price:

693.00 589.05

693.00 589.05

Imiquimod-d9 is intended for use as an internal standard for the quantification of imiquimod (Item No. 14956) by GC- or LC-MS. Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 ?M).{23982} It increases TNF-? and IL-12 p40 production in IFN-?-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.{23979} Topical application of imiquimod (30 ?l of 5% cream) increases TNF and IFN levels at the application site in hairless mice.{43540} Imiquimod dose-dependently increases serum levels of IFN-? in mice when administered by gavage.{43541} It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.{43542} Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-(2-(methyl-d3)propyl-1,1,2,3,3,3-d6)-1H-imidazo[4,5-c]quinolin-4-amine
  • Correlated keywords
    • R-837 S-26308 TMX 101 R837 S26308 Aldara Beselna Zyclara TNF? IL12 IFN? HSV2 deuterated deuterium
  • Product Overview:
    Imiquimod-d9 is intended for use as an internal standard for the quantification of imiquimod (Item No. 14956) by GC- or LC-MS. Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 ?M).{23982} It increases TNF-? and IL-12 p40 production in IFN-?-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.{23979} Topical application of imiquimod (30 ?l of 5% cream) increases TNF and IFN levels at the application site in hairless mice.{43540} Imiquimod dose-dependently increases serum levels of IFN-? in mice when administered by gavage.{43541} It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.{43542} Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.

We also advise you